RxDoctor Payments DataLook up a doctor →

Michelle Price, APRN

Adult Health · Charleston, SCNPI 1184117889

Payments from drug & device makers

$12,719in general payments, 2019–2025

Across 703 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Bayer$738
  • Pfizer$619
  • plus $7K from 48 others

What the payments were for

  • Food & beverage$12,699100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,719 in reported general payments places this provider in the 95th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$166,813
Medicare patients
525
Services billed
4,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$143,193
FarxigaDapagliflozin Propanediol74$83,160
MounjaroTirzepatide49$61,490
RybelsusSemaglutide12$31,780
JanuviaSitagliptin Phosphate29$30,795
EliquisApixaban27$29,588
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$27,232
JardianceEmpagliflozin19$25,183
TrulicityDulaglutide11$13,562
SymbicortBudesonide/Formoterol Fumarate19$8,724
Duloxetine Hcl78$3,795
SynthroidLevothyroxine Sodium50$3,202
Rosuvastatin Calcium194$2,573
Omeprazole133$2,145
Atorvastatin Calcium197$1,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,053$174,973107 claims
AstraZenecaFarxiga, Symbicort$1,043$91,88493 claims
Lilly USA, LLCMounjaro, Trulicity$1,217$75,05260 claims
MerckJanuvia$193$30,79529 claims
PfizerEliquis$619$29,58827 claims
GSKTrelegy Ellipta$449$27,23226 claims
Boehringer IngelheimJardiance$317$25,18319 claims
AbbVieSynthroid$1,332$3,20250 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$98$1,461167 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 adult health providers in South Carolina.

Other adult health in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →